Genentech ends studies on drug combo safety issue - Forbes
Genentech ends studies on drug combo safety issue Forbes - AP 07.14.08, 6:35 PM ET Biotechnology company Genentech Inc. ended several studies combining its cancer drug Avastin and Pfizer Inc.'s Sutent because several patients developed a type of anemia. UPDATE 1-Genentech warns of anemia in Avastin combo trial FDA: Genentech's Avastin Tied To Several Cases Of Anemia |